DiaCarta and MIODx Join Forces to Develop a Diagnostic Test to Predict Patient Responses to Immunotherapy
MIODx and DiaCarta announced today that they have entered into an agreement for the development of a diagnostic test for immunotherapy. The test is based on MIODx’s ClonoMap™ immune sequencing platform, and is designed to predict patient response to immunotherapy, which will be developed and validated at DiaCarta’s CLIA labs in both the San Francisco Bay Area and Nanjing, China. The product will be manufactured at DiaCarta’s ISO 13485 certified GMP manufacturing facility. Immunotherapies have shown great promise in the treatment of cancer, but only some patients respond to therapy. “With this agreement, MIODx’s ClonoMap™ technology will complement DiaCarta’s well-established business in molecular diagnostics, and advance a much needed test for patients undergoing immunotherapy,” said Aiguo (Adam) Zhang, Ph.D., Founder and CEO of DiaCarta.
“With the well-established CLIA and ISO manufacturing facility at DiaCarta, also the experienced IVD team and sales channels in the U.S., Europe and China, we are able to speed up our MIODx’s ClonoMap™ technology to the global market, especially the huge market potential in China. We are very eager to see the impact of the test to benefit patients undergoing immunotherapy,” said M. Allen Northrup, Ph.D., CEO of MIODx.
DiaCarta is a translational genomics and personalized diagnostics company based in Richmond, California with significant business operations in China. DiaCarta provides highly sensitive and advanced XNA technologies that will improve the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. With over 20,000 square feet dedicated to a GMP-compliant lab space as well as CLIA and ISO 13485 certifications, DiaCarta is changing the landscape of molecular diagnostics.
MIODx is an early-stage immunogenomics company based in San Jose, California. The company has developed the ClonoMap™ TCR and BCR sequencing platform that can be used to design diagnostic tests, discover new immunotherapies, or interrogate a person’s immune system. The company is applying the platform to develop diagnostic tests in oncology to help patients have a medically improved outcome.
DiaCarta Expands Board Leadership with Industry Veteran
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, today announced the appointment of Jack Kaye, retired Partner with Deloitte LLP, as an independent board member who will serve as the Chairman of the Company’s Audit Committee.
DiaCarta Enters a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Develop Cancer Tests based on its Novel XNA Technology
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that the company, under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, will collaborate on the evaluation and development of DiaCarta’s proprietary xeno-nucleic acid (XNA) molecular clamping technology. NCI and DiaCarta will collaborate on the following projects: (1) the investigation of low frequency mutation events in cancers and rare diseases using DiaCarta’s proprietary xeno-nucleic acid (XNA) molecular clamping technology, and (2) the development of XNA probes for in situ cancer cell detection. The duration of the CRADA will be 2 years from the effective start date.
DiaCarta’s Multivariant COVID-19 Test Accurately Detects the Omicron Variant
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy announced today that the company has developed a novel test to detect the newest COVID-19 Omicron variant, based on its proprietary XNA technology.
DiaCarta and the Scientific World Mourns the Passing of CSO, Michael J. Powell, Ph.D.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel virology and oncology tests, mourns the passing of Michael “Mike” J. Powell, Ph.D., Chief Scientific Officer of DiaCarta.
DiaCarta Receives CE/IVD for its New COVID 19 Test that Identifies Delta Plus and New Variants
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that its new QuantiVirus™ SARS-CoV-2 Variant Detection Test received the CE/IVD marking and therefore, can now be commercialized within the EU and rest of the world. This new test screens for the SARS-CoV-2 virus and simultaneously identifies and differentiates all the new mutating COVID 19 variants including the Alpha (UK), Beta (S. Africa), Gamma (Brazil), Delta (India), Delta Plus (India), Epsilon (California) and the Kappa (India) variants.